Drug Profile
Research programme: pain therapeutic - Oroxcell
Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Oroxcell
- Class Analgesics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pain
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Pain in France (unspecified route)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Pain in France
- 19 Jul 2016 Preclinical development is ongoing in France